Form 4: Invivyd CCO Granted 675,000 Stock Options

Invivyd's Chief Commercial Officer, Timothy Edward Lee, was granted 675,000 stock options with an exercise price of $1.85, vesting over three years.

Summary

• Timothy Edward Lee, Chief Commercial Officer of Invivyd, Inc. (IVVD), was granted 675,000 stock options.
• The options have an exercise price of $1.85 per share.
• The grant date for these options was January 29, 2026.
• The options vest over a three-year period, with 1/36th of the shares vesting in substantially equal monthly installments, starting one month after the grant date.
• The expiration date for these options is January 28, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates management's long-term commitment and aligns executive incentives with shareholder interests, though it doesn't reflect immediate operational performance.

Positives

• The grant of stock options to the Chief Commercial Officer aligns management incentives with long-term shareholder value.
• The options have a long expiration date of January 28, 2036, providing ample time for potential value realization.

Risks

• The value of the options is dependent on the future stock price of Invivyd, Inc. exceeding the exercise price of $1.85.
• Vesting is subject to continuous service, meaning the options could be forfeited if the officer leaves the company before full vesting.

Future Outlook

The grant of long-term stock options suggests a management incentive structure tied to future company performance and stock price appreciation over the next decade.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Commercial Officer is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate talent, aligning their long-term interests with the company's success and shareholder value creation.

Comparison to Industry Standards

• The grant of 675,000 options to a Chief Commercial Officer is a significant equity award, common in growth-oriented biotech firms where executive compensation often includes substantial equity components to incentivize innovation and market penetration.
• The 10-year expiration period is typical for executive stock options, providing a long-term incentive horizon.
• The three-year monthly vesting schedule is a standard approach to ensure executive retention and sustained performance.

Related Party Transactions

• Grant of 675,000 stock options to Timothy Edward Lee, the Chief Commercial Officer, with an exercise price of $1.85, vesting over three years.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the stock price appreciates and the CCO's incentives lead to improved company performance.
• Employees: May signal confidence in the company's future and a commitment to retaining key talent.
• Management: Provides a significant long-term incentive for the Chief Commercial Officer to drive company growth and profitability.

Next Steps

• The options will begin vesting one month after January 29, 2026, in monthly installments over three years.
• Timothy Edward Lee will continue to hold the 675,000 stock options, subject to vesting conditions.

Key Dates

Recommendation

The filing reports a standard executive stock option grant, which aligns management incentives with long-term shareholder value. However, it does not provide new operational or financial performance data to warrant a change in investment stance. Investors should continue to monitor the company's fundamental performance and market conditions.

Keywords

Invivyd, IVVD, Stock Options, Insider Transaction, Form 4, Executive Compensation, Equity Grant, Chief Commercial Officer